Company / Accounts Receivable
PALVELLA THERAPEUTICS, INC. Accounts Receivable History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$358.0K
FY2024
5-year range
$0 / $5.8M
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#110 of 115
Health Care
What the data says
Among 115 Health Care companies, PALVELLA THERAPEUTICS, INC. is in the bottom 4% for accounts receivable. Accounts Receivable has fluctuated over the past 10 years, ranging from $0 in FY2023 to $16M in FY2017.
Based on SEC 10-K filings.
$358,000 in FY2024 with a 5-year CAGR of -44.5%.
Declined from $6M to $358,000 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -52.4%
- 5-Year CAGR
- -44.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 115This company $358.0K Sector average $1.1B
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -44.5%, indicating a declining trend.
- Ranks #110 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2017.
- Lowest accounts receivable in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $358.0K | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $5.8M | +75.4% |
| FY2021 | $3.3M | +94.2% |
| FY2020 | $1.7M | -74.9% |
| FY2019 | $6.8M | +151.3% |
| FY2018 | $2.7M | -82.6% |
| FY2017 | $15.5M | +27173.7% |
| FY2016 | $57.0K | - |
| FY2015 | $0 | - |
As of FY2024 · SEC 10-K Annual Filings · Updated Jun 30, 2026